News and Educations

Start of a review concerning the conduct of studies at Micro Therapeutic Research Labs, India

16.12.2016

The European Medicines Agency (EMA) has started a review of medicines for which studies have been conducted by Micro Therapeutic Research Labs at two sites, Chennai and Coimbatore, in India. This follows a good clinical practice (GCP) inspection which raised concerns about the study data used to support marketing authorisation applications of some medicines in the EU. The inspection was carried out jointly by Austrian and Dutch authorities in February 2016 in the context of the evaluation of applications for nationally authorised medicines.

Having considered the inspection findings, several national medicines regulatory agencies (Austria, Bulgaria, Croatia, Denmark, Estonia, Finland, Germany, Hungary, Iceland, Latvia, the Netherlands, Norway, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom) requested EMA to assess the impact of these findings on the benefits and risks of medicines authorised in the EU. EMA has also been requested to look at the impact on medicines which are currently being evaluated for authorisation and which use study data from these sites.

EMA will now review the available data to determine if any action is necessary to protect public health.

More about the medicines

The review covers one medicinal product authorised centrally through EMA (Tadalafil Mylan), as well as medicines authorised by national procedures in individual EU Member States, whose marketing authorisation applications included data from studies conducted by Micro Therapeutic Research Labs at two sites in India:

The review is being carried out by the Committee for Medicinal Products for Human Use (CHMP), responsible for all questions concerning medicines for human use, which will adopt an opinion. The CHMP opinion will then be forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU Member States.